All In Biotech

Drug Trial Radar · NCT07261150

Histoplasmosis Induction and Consolidation Therapy Factorial Randomized Clinical Trial (Histo-FACT)

Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 664 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

664

Planned (sponsor's estimate)

Start

Dec 1, 2026

Primary completion

Dec 31, 2030

Study completion Dec 31, 2030

Sponsor

Lead sponsor
University of MinnesotaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Federal University of Health Science of Porto Alegre
First posted
Dec 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is threefold: 1. Assess the safety and efficacy of a single high-dose intravenous (LAmB 10mg/kg) compared to the SOC daily dosing (3mg/kg) of the same medication for induction therapy in moderate to severe histoplasmosis. 2. Assess the safety and efficacy of oral posaconazole 300mg delayed-release tablets three times daily for two days then once daily for consolidation therapy compared to SOC oral itraconazole 200 mg capsules three times daily for three days then twice daily in moderate to severe histoplasmosis 3. Assess the safety and efficacy of 6 months of consolidation therapy compared to the SOC 12 months of consolidation therapy in persons with HIV on appropriate antiretroviral therapy.

Conditions

  • Histoplasmosis

Interventions

  • LAmB BDrug

    intravenous liposomal amphotericin B (10mg/kg)

  • PosaconazoleDrug

    Posaconazole delayed-release tabs, 300mg twice daily on day 1 then once daily

  • World Health Organization (WHO)-recommended SOCDrug

    daily intravenous liposomal amphotericin B 3mg/kg, for 2 weeks or at least 7 days if felt stable for discharge per the clinician

  • WHO-recommended SOC ItraconazoleDrug

    200mg capsules three times daily x 3 days then twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mortality at 2 weeksTime frame: Week 2
  2. Mortality at 26 weeksTime frame: Week 26
  3. SAE-free survival between 26 and 52 weeks from induction therapy among those who survived 26 weeksTime frame: Week 52

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Minnesota

    Minneapolis, Minnesota

  • Universidade Federal de Ciências da Saúde de Porto Alegre

    Porto Alegre, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.